Skip to content

Abstract B079: Disparities in treatment receipt and reasons for non-treatment in advanced gastrointestinal cancers

Oct 2026 · Cancer Epidemiology, Biomarkers & Prevention · Vol 35, pp. B079-B079 · 0 citations

TL;DR

Pat, socioeconomic, and healthcare factors were associated with both non-receipt of cancer-directed treatment and reasons for non-treatment among patients with advanced GIC, suggesting that potentially modifiable healthcare access and care delivery factors may contribute substantially to treatment non-receipt.

Abstract

Gastrointestinal cancers (GIC) account for substantial morbidity and mortality, yet a significant proportion of patients do not receive cancer-directed treatment. The reasons underlying non-treatment remain poorly characterized. We evaluated factors associated with non-receipt of treatment and, among untreated patients, factors associated with reasons for non-treatment. We conducted a retrospective cohort study using the National Cancer Database (NCDB), including adults with stage III–IV colon, esophageal, liver, pancreatic, rectal, and gastric cancers diagnosed from 2016–2023 (N=487,414). Treatment status was defined as receipt of ≥1 cancer-directed modality versus no treatment. Among untreated patients (n=113,031), reasons for non-treatment were classified as contraindication/death, refusal, or not planned. Two nested analyses evaluated: (1) clinical (contraindication/death) versus non-clinical reasons and (2) refusal versus treatment not planned among patients without documented clinical reasons. Missing data were addressed using multiple imputation. Multivariable generalized estimating equation logistic regression models estimated adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Overall, 23.2% of patients did not receive cancer-directed treatment. Compared with patients aged 18–49 years, the odds of non-treatment increased with age, reaching more than fourfold higher among those aged ≥75 years (OR 4.24, 95% CI 4.07–4.43). Compared with privately insured patients, uninsured (OR 2.34, 95% CI 2.19–2.49), Medicaid-insured (OR 1.53, 95% CI 1.49–1.57), and Medicare-insured patients (OR 1.30, 95% CI 1.27–1.34) had higher odds of non-treatment. Non-Hispanic Black patients had higher odds of non-treatment than Non-Hispanic White patients (OR 1.14, 95% CI 1.11–1.17). Among untreated patients, 20.7% had contraindication/death, 12.5% refused treatment, and 66.8% had treatment not planned. Among untreated patients, Non-Hispanic Black patients had higher odds of a documented clinical reason for non-treatment (OR 1.20, 95% CI 1.14–1.25), whereas female (OR 0.94, 95% CI 0.91–0.97) and uninsured patients (OR 0.87, 95% CI 0.80–0.95) had lower odds. Among patients without clinical reasons, older age and women had greater odds of treatment refusal, while Hispanic (OR 0.91, 95% CI 0.84–0.97) and Non-Hispanic Black patients (OR 0.79, 95% CI 0.75–0.84) had lower odds of refusal versus treatment not planned. Patient, socioeconomic, and healthcare factors were associated with both non-receipt of cancer-directed treatment and reasons for non-treatment among patients with advanced GIC. Distinct patterns were observed for clinical versus non-clinical reasons for non-treatment. Notably, most untreated patients had treatment not planned rather than documented contraindications/death or treatment refusal, suggesting that potentially modifiable healthcare access and care delivery factors may contribute substantially to treatment non-receipt. Maira A. Castañeda-Avila, Jonggyu Baek, Tasneem Ali, Raiya A. Suliman, Akua Serebou, Kate L. Lapane. Disparities in treatment receipt and reasons for non-treatment in advanced gastrointestinal cancers [abstract]. In: Proceedings of the 19th AACR Conference on the Science of Cancer Health Disparities; 2026 Oct 18-21; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2026;35(10 Suppl):Abstract nr B079.

View source

Similar papers

Review Open access Oct 2026

Reasons for delay in receipt of neoadjuvant chemotherapy in patients with muscle invasive bladder cancer.

178 Background: Delay in time from muscle invasive bladder cancer (MIBC) diagnosis to neoadjuvant chemotherapy (NACT) > 60 days, can negatively impact cancer related outcomes. However, the underlying causes of these delays remain poorly characterized, underscoring the need for further investigation. Methods:...

Margaux Wooster, Abha Kulkarni, R. Raghunathan et al. · 0 citations
Sep 2026

Abstract A137: Chemotherapy utilization and outcomes in patients with metastatic pancreatic adenocarcinoma

In a large cohort of patients with de novo mPDAC, more than half of patients were untreated or unable to tolerate CTx, possibly related to older age and worse PS, and this findings highlight a significant need for improved treatment options for mPDAC.

Shubham Pant, P. Pradhan, Yue-Xi Wang et al. · 0 citations
Open access Sep 2026

Factors Associated with Palliative-Intent Treatment Receipt in Cutaneous T-Cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a chronic, generally incurable group of non-Hodgkin lymphomas associated with substantial symptom burden, yet receipt of palliative-intent treatment in this population remains uncharacterized. We conducted a cross-sectional retrospective study of 13,215 patients with CTCL using the N...

Arya Patel, Mohammad Saleem, N. Yusuf · 0 citations
Review Open access Oct 2026

Screen failure among patients consenting for early phase cancer clinical trials (EPCTs).

107 Background: EPCTs represent an important treatment option for patients with cancer. However, trials often have strict eligibility criteria and screen failures (SF) can limit enrollment. We sought to identify reasons for SF among potential EPCT participants, evaluate associations between SF and overall survi...

S. Durbin, Andrea Pelletier, N. Teeyapun et al. · 0 citations
Review Oct 2026

Abstract C159: Treatment determinants and outcomes among endometrial cancer patients: A systematic review

The burden of endometrial cancer (EC), the most frequently diagnosed gynecologic cancer in the US, continues to rise, with EC mortality disproportionately affecting marginalized communities. This systematic review synthesizes evidence on treatment-related outcomes and multi-level determinants of care among US pat...

Brianna D. Taffe, Cecilia A. Cortez, Charlotte Ellis et al. · 0 citations
Open access Oct 2026

Routes to diagnosis and survival in Danish patients with non–small cell lung cancer: the impact of emergency admission

ABSTRACT Background Worldwide, lung cancer remains the leading cause of cancer-related death. Studies have shown that receiving a lung cancer diagnosis following an unplanned admission is associated with poor prognosis. The causal relationship between emergency presentation and survival remains uncertain. Methods We co...

N. L. Christensen, K. Kristensen, T. Rasmussen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.